Business Overview
Executive Team
Board of Directors
Scientific Advisory Board
SEC Filings
Investor FAQ
Investor Info
Contact Us
Market Overview
Disease Overview
Competition Overview
Cerebain Solution
Like a thief in the night, Alzheimer’s disease robs a person of a lifetime of memories. It is estimated that about 35 million people have dementia worldwide. This figure is likely to nearly double every 20 years to nearly 115 million in 2050. There are about 5.2 million Americans who have already been diagnosed with Alzheimer’s disease and about 1,000 new cases of the disease are diagnosed daily in the United States.

At Cerebain Biotech, we believe that our unique Omentum methodology for Alzheimer’s patients has a great potential to reverse the effects of this debilitating disease.
Above is a picture of the prototype which is being developed to provide continuous Omentum stimulation, enabling substantial advancements in the treatment efficiency and the quality of life of Alzheimer's patients.
© 2010 - 2013 Cerebain Biotech Corp.
Terms of Use
Privacy Policy